Nasus Pharma (NSRX) Profit After Tax (2024)

Nasus Pharma (NSRX) reported Profit After Tax of -$885000.0 for Q4 2024.

Nasus Pharma (NSRX) Profit After Tax (2024) Analysis & Trends

Nasus Pharma has reported Profit After Tax for 1 years, with the latest figure at -$885000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.48 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.24 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Nasus Pharma 23.47 Mn 19.18 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -885,000.00